Myriad Genetics Inc (MYGN) Q2 2021 Earnings Call Transcript
MYGN earnings call for the period ending December 31, 2020.
Myriad Genetics
MYGN
MYGN
$30.21
$0.11
0.4%
Price as of February 25, 2021, 9:00 p.m. EST
View Interactive MYGN Charts
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
Interactive Chart
News & Analysis: Myriad Genetics
The Fool has written over 200 articles on Myriad Genetics.
Myriad Genetics Inc (MYGN) Q1 2021 Earnings Call Transcript
MYGN earnings call for the period ending September 30, 2020.
COVID-19 Pandemic Wreaks Havoc on Myriad Genetics' Fiscal Q4 Results
But there were a few encouraging signs for the molecular-diagnostics company.
Myriad Genetics Inc (MYGN) Q4 2020 Earnings Call Transcript
MYGN earnings call for the period ending June 30, 2020.
Here's Why Myriad Genetics Is Tumbling Today
Coronavirus testing is up, but the pandemic has hammered demand for Myriad's hereditary cancer tests.
Myriad Genetics Inc (MYGN) Q3 2020 Earnings Call Transcript
MYGN earnings call for the period ending March 31, 2020.
Genetic Testing Stocks Rise Again as Volatility Continues
Have these growth stocks bottomed out? That's probably the wrong question to ask.
Should You Buy These 2 Prenatal Testing Stocks?
More babies are born in summer and early fall than other times of year, meaning mothers-to-be are likely undergoing prenatal testing now. Can investors profit?
Myriad Genetics CEO Mark Capone Resigns
The molecular diagnostics company also delivered an earnings miss, and its stock plunged.
Why Myriad Genetics Shares Are Tanking Today
The molecular diagnostics company's latest quarterly results weren't anywhere close to what Wall Street expected.
